Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia.

ABSTRACT:

Background

We aim to analyze the efficacy and safety of Venetoclax (Ven) added to cladribine + cytarabine + granulocyte colony-stimulating factor (G-CSF) ± idarubicin or mitoxantrone (CLAG ± Ida/Mito) regimen as a salvage treatment of relapsed/refractory acute myeloid leukemia (RR-AML).

Methods

A single-center, retrospective, cohort study was performed. Patients with RR-AML, being treated with CLAG ± Ida/Mito with versus without Ven, were retrospectively studied. The endpoints of this study were to evaluate the rate of composite complete remission (CRc), measurable residual disease (MRD), event-free survival (EFS), overall survival (OS), and relapse between CLAG and CLAG + Ven groups.

Results

Sixty-nine patients were included, with a median age of 37 (range, 18-65) ye

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC11811969 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature